Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

Over 100 scientists have slammed Lancet Medical Journal over its study on using hydroxychloroquine (HCQ) to treat Covid-19. The authenticity of the study is under question. WION's Palki Sharma gets you a report.

Gravitas: Was Lancet study on Hydroxychloroquine fabricated?

lancet-study-on-hydroxychloroquine

Lancet Study On Hydroxychloroquine, News on Lancet Study On Hydroxychloroquine, stories on Lancet Study On Hydroxychloroquine, articles on Lancet Study On Hydroxychloroquine, Lancet Study On Hydroxychloroquine stories at Wion, Lancet Study On Hydroxychloroquine news, Lancet Study On Hydroxychloroquine latest news

lancet study-on-hydroxychloroquine

Lancet opens probe into ‘unreliable’ anti-stroke medicine

Gravitas: Was Lancet study on Hydroxychloroquine fabricated?